Pursuant to the provisions of Regulation 30 read with sub-para 20, Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Bliss GVS Pharma has submitted the disclosure regarding Audit observation letter imposing GST liability with interest & penalty against the Company. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided ‘Annexure-I’.
The above information is a part of company’s filings submitted to BSE.
